Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-09-11
2007-09-11
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S135100, C424S139100, C424S141100, C424S142100, C424S152100, C424S172100
Reexamination Certificate
active
10298461
ABSTRACT:
The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.
REFERENCES:
patent: 5972338 (1999-10-01), Godowski et al.
patent: 6074873 (2000-06-01), Fong et al.
patent: 6596850 (2003-07-01), Huse
patent: 2003/0077809 (2003-04-01), Ruben et al.
patent: WO99/15654 (1999-04-01), None
patent: WO99/55869 (1999-11-01), None
patent: WO99/67382 (1999-12-01), None
patent: WO 99/67382 (1999-12-01), None
patent: WO 00/53757 (2000-09-01), None
Kiang et al., Pharmacol Ther. 1998, vol. 80(2): 183-201.
Brooks et al., Cell 1994, vol. 79(7): pp. 1157-1164.
Sun et al., J Cancer Res Clin Oncol. 1999, vol. 125(7): pp. 419-426.
Philip S., Cancer Pract. 2000, vol. 8(3): pp. 148-150.
Medina et al. 2004. Hepatology 39:1185-1195.
Andersen et al. 1997. Electrophoresis 18:533-537.
Camenisch G et al. 2002. JBC 277:17281-17290.
Goodman and Gilman, The Pharmacological Basis of Therapeutics. 10th edition, McGraw-Hill, 2001, p. 3-29.
Charnow et al. 1996 Trends Biotech 14:52-60.
Carter P. 2001. J Immunol Methods 248:7-15.
Camenisch Gieri et al., 2002,Journal of Biological Chemistry, 277(19):17281-17290 “ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin avβ3and Induces Blood Vessel Formation in Vivo”.
Conklin D et al., 1999,Genomics, 62(3):477-482 “Identification of a Mammalian Angiopoietin-Related Protein Expressed Specifically in Liver”.
Yokoyama Kenji et al., 2000,Journal of Biological Chemistry, 275(22):16891-16898 “Identification of Amino Acid Sequences in Fibrinogen γ-Chain And Tenascin C C-terminal Domains Critical for Binding to Integrin avβ3”.
Supplementary Partial European Search Report dated Jun. 29, 2005, for European Patent Application No. EP 02 78 2310.
Camenisch, et al., 2002,The Journal of Biological Chemistry, 277(19):17281-17290 “ANGPTL3 Stimulates Endothelial Cell Adhesion and Migration via Integrin αvβ3and Induces Blood Vessel Formation in Vivo”.
Carron et al., 1998,Cancer Research, 58:1930-1935 “A Peptidomimetic Antagonist of the Integrin αvβ3Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy”.
Conklin et al., 1999,Genomics, Academic Press, San Diego, U.S., 62(3):477-482 “Identification of a Mammalian Angiopoietin-Related Protein Expressed Sepcifically in Liver”.
Friedlander et al., 1996,Proc. Natl. Acad. Sci. USA, 93:9764-9769 “Involvement of integrins αvβ3and αvβ5in ocular neovascular diseases”.
Kerr et al., 1999,Anticancer Research, 19:959-968 “Novel Small Molecule αv Integrin Antagonists: Comparative Anti-Cancer Efficacy with Known Angiogenesis Inhibitors”.
Kumar et al., 2001,Cancer Research, 61:2232-2238 “Inhibition of Angiogenesis and Tumor Growth by SCH221153, a Duial αvβ3and αvβ5Integrin Receptor Antagonist”.
Lark et al., 2001,Journal of Bone and Mineral Research, 16(2):319-325 “Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat”.
Xiong et al., 2001,Science, 294:339-345 “Crystal Structure of the Extracellular Segment of Integrin αVβ3”.
Xiong et al., 2002,Science, 296:151-155 Crystal Strucutre of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand.
Yokoyama et al., 2000,Journal of Biological Chemistry, 275(22):16891-16898 “Identification of amino acid sequences in fibrinogen gamma-chain and tenascin C C-terminal domains critical for binding to integrin alphavbeta3”.
Supplementary Partial European Search Report dated Jun. 29, 2005 and mailed Dec. 19, 2005.
Ferrara Napoleone
Gerber Hans-Peter
Kowalski Joe
Pisabarro Maria Teresa
Sherman Daniel Eric
Genentech Inc.
Merchant & Gould P.C.
Shafer Shulamith H.
LandOfFree
Composition comprising and method of using angiopoietin-like... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition comprising and method of using angiopoietin-like..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition comprising and method of using angiopoietin-like... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3728311